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recorded, and compared to the recorded date of BOS diag-
nosis. Fisher's exact test was applied to determine statistical
signiﬁcance where applicable.
Results: For all BOS patients, the mean time from trans-
plantation to diagnosis of BOS was 478 days (95% CI
357-599d) compared to amean time of 169 days (95% CI 100-
238d) when patients had either an FEV1<90% or FEF25-75
<75%. The mean difference was 298 days (95% CI 176-420d,
P ¼ .00003). Patients with cGVHD and no BOS had similar
decline in PFT in only 22/44 patients, compared to 100% of
those with BOS. Serum IGF-1 values were > 4,000 (25th
percentile) in 12 of 13 patients with BOS (P ¼ .04). Overall, 12
of 13 patients had biomarkers elevation prior to spirometric
diagnosis of BOS.
Conclusions: Application of the BOS 0-p criteria to HSCT
patients may identify patients at risk for BOS at an earlier
time point. The use of the IGF 1 as a serum biomarker may
also contribute to identify patients at risk, although further
studies are needed to investigate whether this marker can
differentiate between patients with BOS and those with
other lung diseases.417
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Haploidentical (HI) HSCT with low dose donor T-cell infusion
provides a survival advantage in tumor bearing mice when
compared to parent F1 or MHC-matched transplant models.
We suggest thatMHC difference in HI-HSCTgenerates early T-
cell clonal activation against the unshared MHC haplotype,
which eliminates residual tumor cells that express the
unsharedMHChaplotype.However, alteration inMHCantigen
expression is a signiﬁcant contributor to tumor escape from
graft-versus-tumor (GVT) activity. Recent haploidentical
transplant data revealed that uniparental disomy, the loss of
theHLAhaplotype, is a clinically relevantmechanismof tumor
escape that leads to post-transplant leukemia relapse. Murine
renal cell carcinoma, RENCA cell line normally expresses only
H2Kdas a MHC molecule. Therefore, in our haploidentical
transplant model, T cell clonal activity is usually restricted
against H2Kdmolecule only. For circumventing the single
haplotype expression of tumormodel, we transfected this cell
line with a H2Kbexpressing vector, pAcGFP-NeoR-H2Kb, and
generatedstable cloneswithG418 selection. The clone thathas
more than 95% H2Kbexpression used for in vivo experiments.
Both tumor cell lines, i.e. parental and transfected clone, had
similar in vivo tumor growth acceptance and growth rate. We
then used two different haploidentical donors that were tar-
geting different MHC haplotypes. Lethally irradiated B6D2F1
(H2Kb/d) mice were transplanted with T cell depleted bone
marrow(TCD-BM) fromeitherB6C3F1(H-2Kb/k) (singlehaplo-
1; SH1), or C3D2F1 (H2Kk/d) (single haplo 2; SH2) or both
donor mice with low-dose (1x105) T-cells. In some experi-
ments, animals were also injected either H2Kdor H2Kb/
d expressingRENCA-TGL cells for the evaluationofGVTactivity
Bone marrow (BM), spleens and thymi were harvested from
recipients of single and double HI-HSCT at day 35 and
showed similar cellularities. Interestingly, spleen and bonemarrow had similar chimerism from both donors in DH-
HSCT. There were no early transplant mortality, graft failure,
weight loss and GVHD scoring difference among the double
or single-haploidentical transplant recipients. In two other
sets of experiments, we followed the tumor growth and the
survival of tumor bearing mice after transplant. The recipi-
ents of DH-HSCT showed a better survival and GVT activity
than the recipients of SH-HSCT in RENCA-TGL (H2Kb/d)
bearing tumor model. These observations conﬁrmed that
MHC targeting plays a prominent role in tumor surveillance,
and immune targeting the unshared MHC haplotype with
haploidentical transplant induce remarkable survival
advantage.418
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Background: The most widely used mice model of chronic
graft-versus-host disease (cGvHD) is an MHC-matched bone
marrow transplantation model of sclerodermatous cGvHD. A
limitation of that model is that mortality is relatively low,
making difﬁcult to study the impact of potentially thera-
peutic compounds.
Aims: To develop a more severe model of cGVHD and to
assess the impact of Rapamycin administration in that
model.
Results: Lethally irradiated Balb/C mice were injected with
10x106 bone marrow cells and 70x106 splenocytes from
B10.D2 donor mice. Twenty-one days later, all mice devel-
oped cGvHD. For the severe model, donor B10.D2 mice were
injected with 0.5x106 splenocytes from Balb/C twenty-one
days before transplantation. All mice from the severe model
(n¼8) died a median of 32 days while 3 of 7 mice in the
classical model survived beyond day 52. Mean survival was
decreased in the severe model compared to the classical
model (32 days versus 37 days; p¼0.0185). Recipient mice in
the severe group experienced higher weight loss, hair loss
and skin ﬁbrosis. Numbers of T lymphocytes (251.9  151.4
versus 626.3  532.8; p¼0.0004) and CD4+ T cells (61.57 
41.93 versus 125.0  14.39; p¼0.0008) per microliter of
blood at day 21 were lower in the severe group than in the
classical model. Moreover, number of regulatory T cells
(Tregs) was decreased in the severe model (0.9870  0.8864
versus 7.979  6.753; p¼0.0062).
We then investigated whether rapamycin administration
could prevent GVHD in the severe model. All (n¼8) mice
treated with PBS (placebo) died a median of 32 days after
transplantation, while 6 of 8 mice given 1mg/kg/day i.p.
rapamycin survived beyond day 52 (p¼0.0012). Number of
Tregs/ml was higher at day 21 in rapamycin-treatedmice than
in mice given PBS (3.532  1.195 versus 1.958  0.8864;
p¼0.0796). Moreover, number of naïve CD4+T (7.798  4.192
versus 25.71  5.185; p¼ 0.0276), effector memory CD4+ T
cells (EMT) (40.50  3.180 versus 25.17  7.881; p¼ 0.0392)
and central memory CD4+ T cells (CMT) (53.58 3.180 versus
26.29  7.881; p¼ 0.0060) were higher in rapamycin mice.
Finally, proliferation of EMT (assessed by ﬂow cytometry
using Ki-67) (34.70%  4.084 versus 30.80%  2.003;
p¼0.0221) and CMT (33.25%  4.084 versus 27.50%  2.003;
p¼0.0183) was higher in PBS than in rapamycin mice.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S313eS341S318Conclusion: We have developed a mice model of severe
cGVHD. Interestingly, rapamycinpreventeddeath fromcGVHD
in that model, perhaps through in vivo expansion of Treg.419
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Graft-versus-host disease (GVHD) frequently causes
morbidity and mortality after allogeneic hematopoietic cell
transplantation (HCT). In HLA-identical HCT, GVHD results
from donor T cell recognition of minor histocompatibility (H)
antigens on recipient tissues. Complete T cell depletion (TCD)
of donor hematopoietic cell products is more effective than
pharmacologic immunosuppression for preventing GVHD,
but is complicated by delayed immune reconstitution and
consequent life-threatening infections. Approaches to HCT
that preferentially deplete T cells responsible for GVHD and
preserve pathogen-speciﬁc T cells may improve outcomes.
Mature CD3+CD8+ and CD3+CD4+ T cells can be classiﬁed into
CD45RA+CD62L+ naïve (TN) and CD45RO+ memory (TM)
subsets, the latter of which includes effector memory (TEM)
and central memory (TCM) T cells. Murine studies in MHC-
matched and emismatched models demonstrated that
transplanting TN cells causes severe GVHD, puriﬁed TCM
causes mild GVHD, and TEM do not cause GVHD. In vitro
studies have similarly demonstrated that human donor CD8+
T cells speciﬁc for recipient minor H antigens are found
predominantly within the TN cell subset. In sum, these data
suggest that selective TNcell depletion may alter the inci-
dence or severity of GVHD in human HCT.
We developed an effective process for engineering human
peripheral blood stem cell (PBSC) grafts that depletes
CD45RA+ TN and retains CD34+ stem cells and functional
CD45RO+ TM speciﬁc for diverse opportunistic pathogens.We
initiated a clinical trial to evaluate selective depletion of TN
cells from allogeneic PBSC for the prevention of GVHD in
patients with acute leukemia. Each of the ﬁrst 22 patients has
engrafted (median day 12), regimen-related toxicity has
been acceptable, T-cell numbers recover faster than reported
for TCD HCT (median 412 CD3+ T cells/ml on day 28), and
there is no increase in the rate of relapse, opportunistic
infections, or EBV reactivation compared to patients treated
with T cell replete PBSC grafts. Early onset gastrointestinal
symptoms that are compatible with mild acute GVHD occur
frequently, but rapidly respond to therapy, and most patients
have successfully tapered immunosuppression. T cell
responses to pathogens recover early after HCT. At a median
of 14 months follow-up, overall and disease free survival are
80% and 75% respectively, and the frequency and severity of
chronic GVHD is substantially reduced compared to recipi-
ents of T cell replete PBSC grafts.420
Adenovirus PCR-Positivity in Stool Precedes Intestinal
GRAFT Versus Host Disease After Allogeneic
Hematopoietic Stem Cell Transplantation
Jaap Boelens. Department of Pediatrics: Blood and Marrow
Transplantation Program, UMC Utrecht (Wilhelmina Children's
Hospital), Utrecht, NetherlandsIntroduction: Acute graft versus host disease (aGvHD) is
a common (20-50% of all HSCT recipients) and potentially
lethal complication after allogeneic hematopoietic stem cell
transplantation (HSCT). Risk factors for aGvhD include donor
source, preparative regimen and the degree of HLA-mis-
matching. Currently, there is increasing evidence that
(reactivation of) viral infection is a risk factor for aGvHD. We
hypothesized that the presence of viruses in the gastroin-
testinal tract, including AdV, triggers the initiation phase of
intestinal GvHD. Therefore we investigated the association
between viral PCR-positivity in stool prior to HSCT and the
occurrence of intestinal aGvHD.
Methods: We prospectively evaluated 27 consecutive pedi-
atric allogeneic HSCT patients from January ’09 until October
’10. Primary endpoint was the development of intestinal
aGvHD diagnosed according to Gluckbergs criteria and
conﬁrmed by histopathology. Follow-up ranged from 100 to
376 days or until death. Stool specimens were taken peri-
HSCT and analyzed for entero-, -noro-, astro-, -parecho- and
adenovirus, by real-time PCR. The association between fecal
PCR- positivity and intestinal aGvHD was analyzed using
Fisher's exact tests.
Results: Of the 27 patients that were evaluated, 6 (22%)
developed intestinal aGvHD after a median of 64 days (range,
38-74). Four (15%) patients died due to transplant related
complications or disease progression/relapse after 22-61
days. All patients with stool specimens positive for AdV (4/
27, 15%) developed intestinal aGvHD (versus 2 / 23 (9%)
patients without AdV in stool,P ¼ .001, positive predictive
value¼ 100%, negative predictive value¼ 91%). Four patients
were positive for other viruses but none of these developed
aGvHD. Interestingly, one patient became positive for AdV at
327 days post-SCT and developed chronic intestinal GvHD
after 476 days. AdV persisted in patient stool for more than
140 days, and preceded systemic infection: AdV was ﬁrst
detected in plasma on day 409 and loads raised from 482
copies/ml to 1.4*10.4 copies/ml on day 500.
Conclusion: AdV in stool prior to HSCT was associated with
intestinal acute GvHD. It supports the hypothesis that virally
induced tissue damage leads to inﬂux of inﬂammatory
mediators and ultimately activation and inﬂux of activated
cytotoxic T-cells involved in GvhD. Currently we perform
a prospective follow- up study. These results may impact
monitoring and treatment (preventive and curative) guide-
line/protocols.421
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Recent research has increased our understanding of
lymphocyte metabolism in vitro, but the metabolism of
lymphocytes activated in vivo remains poorly understood. To
evaluate this important issue further, we explored the
metabolism of proliferating, donor T lymphocytes seven days
after the initiation of graft versus-host disease (GVHD) in an
acute model of GVHD (B6 into B6D2F1). Donor T cells up-
regulated mRNA for fatty acid (FA) transport proteins (e.g.
